Your browser doesn't support javascript.
loading
Stroke and antiphospholipid syndrome-antiphospholipid antibodies are a risk factor for an ischemic cerebrovascular event.
Gaspersic, Natasa; Zaletel, Marjan; Kobal, Jan; Zigon, Polona; Cucnik, Sasa; Semrl, Snezna Sodin; Tomsic, Matija; Ambrozic, Ales.
Afiliación
  • Gaspersic N; Department of Rheumatology, University Medical Centre Ljubljana, Vodnikova 62, SI-1000, Ljubljana, Slovenia. natasa.gaspersic@kclj.si.
  • Zaletel M; Department of Neurology, University Medical Centre Ljubljana, Zaloska 2, SI-1000, Ljubljana, Slovenia.
  • Kobal J; Department of Neurology, University Medical Centre Ljubljana, Zaloska 2, SI-1000, Ljubljana, Slovenia.
  • Zigon P; Department of Rheumatology, University Medical Centre Ljubljana, Vodnikova 62, SI-1000, Ljubljana, Slovenia.
  • Cucnik S; Department of Rheumatology, University Medical Centre Ljubljana, Vodnikova 62, SI-1000, Ljubljana, Slovenia.
  • Semrl SS; Faculty of Pharmacy, University of Ljubljana, Askerceva 7, SI-1000, Ljubljana, Slovenia.
  • Tomsic M; Department of Rheumatology, University Medical Centre Ljubljana, Vodnikova 62, SI-1000, Ljubljana, Slovenia.
  • Ambrozic A; Faculty of Mathematics, Natural Sciences and Information Technologies, University of Primorska, Glagoljaska 8, SI-6000, Koper, Slovenia.
Clin Rheumatol ; 38(2): 379-384, 2019 Feb.
Article en En | MEDLINE | ID: mdl-30088114
Testing for antiphospholipid antibodies could be an important part in determining the cause of a cerebrovascular event (CVE). Currently, it is also unknown whether antiphospholipid antibodies represent a risk factor for the development of a CVE and whether the selected therapy options are efficacious. So, this study aimed at (1) determining the frequency of patients experiencing a CVE and fulfilling the laboratory criterion for an antiphospholipid syndrome (APS), (2) investigating whether the persistent presence of antiphospholipid antibodies represented a risk factor for a CVE, and (3) focusing on the efficacy of the selected treatment strategy in the first year after the CVE. Eighty-nine patients with an acute CVE were prospectively followed for 1 year. At least two sera from each were tested for lupus anticoagulants, anticardiolipin, anti-ß2-glycoprotein I, anti-phosphatidylserine/prothrombin and anti-annexin V antibodies. Twenty out of eighty-nine (22%) of CVE patients fulfilled the criteria for APS (17/20 for definitive and 3 for probable APS). There was a significant association between persistently present antiphospholipid antibodies and the CVE (OR, 4.62). No statistically significant difference was found in the CVE recurrence rate between APS-CVE and non-APS-CVE patients being treated mainly with acetyl salicylic acid. Antiphospholipid antibodies represent an independent risk factor for a CVE. In the first year after the CVE, antiplatelet therapy seemed to be sufficient in secondary CVE thromboprophylaxis in most APS patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome Antifosfolípido / Anticuerpos Antifosfolípidos / Accidente Cerebrovascular / Tromboembolia Venosa Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Rheumatol Año: 2019 Tipo del documento: Article País de afiliación: Eslovenia Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome Antifosfolípido / Anticuerpos Antifosfolípidos / Accidente Cerebrovascular / Tromboembolia Venosa Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Rheumatol Año: 2019 Tipo del documento: Article País de afiliación: Eslovenia Pais de publicación: Alemania